Epidermal Growth Factor Receptor in Lung Cancer
Author Information
Author(s): R. Dittadi, M. Gion, V. Pagan, A. Brazzale, O. Del Maschio, A. Bargossi, A. Busetto, G. Bruscagnin
Primary Institution: The Center for the Study of Biological Markers of Malignancy, Division of Radiotherapy, Regional General Hospital, ULSS 16, Venice; Thoracics Surgery Section and Service of Pathological Anatomy, Regional General Hospital, ULSS 36, Mestre, Italy.
Hypothesis
The study aims to evaluate the differences of EGFr expression between lung cancer and normal lung tissue, as well as the relationship between EGFr expression and other pathological parameters.
Conclusion
Epidermal growth factor receptor levels are significantly higher in lung cancer tissues compared to normal lung tissues.
Supporting Evidence
- EGFr concentrations in cancer tissues were significantly higher than in normal tissues.
- 57% of cancer cases showed EGFr levels above the defined cut-off point.
- The binding characteristics of EGFr were similar in both cancer and normal tissues.
Takeaway
This study found that lung cancer tissues have more of a specific protein called EGFr than normal lung tissues, which might help doctors understand cancer better.
Methodology
EGFr was measured using a radioligand binding assay in membrane preparations from lung cancer and normal tissue samples.
Limitations
The study's findings may not apply to all types of lung cancer, as it focused on non-small cell lung cancer.
Participant Demographics
Median age of participants was 60 years, with 64% having squamous cell carcinomas, 27% adenocarcinomas, and 9% large cell carcinomas.
Statistical Information
P-Value
0.0002
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website